Alzamend Neuro is trading at $1.48, up 8.03%; broader market gains may be contributing, but no direct link to the move is established.
- U.S. stocks and growth shares were broadly higher on October 5; Reuters reported the Nasdaq at a record as megacap and growth stocks advanced.
- A report noted AL001 dosing in a Phase 2A healthy-volunteer study that began in May; it described shares falling premarket—not the current rise.
- No trading-volume figure was verified.